title: Re: Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin).
authors.forename: Saqib Ali Khan
authors.initials: SA
authors.lastname: Utman
authors.forename: Baljean
authors.initials: B
authors.lastname: Dhillon
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects* / Q000502:physiology; D008268:Macular Degeneration / Q000188:drug therapy*; D019233:Retreatment; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab